A Price Tag That Raises Eyebrows
Let's be clear, Boston Scientific’s bid for Penumbra is an eye-watering sum. Why pay so much for a company specialising in, of all things, sucking out blood clots? The answer is simple. Desperation. The major medical device companies are like enormous, lumbering cruise liners. They are safe and they have immense power, but they turn with all the agility of a tectonic plate. Innovation, real game-changing stuff, doesn't happen in their sprawling corporate labs anymore. It happens in nimbler, faster-moving companies like Penumbra.
Penumbra cracked the code on treating strokes and blood clots with clever thrombectomy devices, making older surgical methods look positively medieval. Boston Scientific could have tried to build something similar in-house, of course. But that would have taken years of research, development, and navigating a regulatory minefield. It was far easier, and quicker, to simply get out the corporate chequebook. The premium they paid tells you everything you need to know about how badly they needed that technology yesterday.
